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Abstract 
Background: Entecavir-resistance mutations are commonly induced by entecavir treatment in chronic hepatitis B 
patients. However, entecavir+adefovir dipivoxil+lamivudine triple-resistance mutations induced by sequential or 
combination treatment with lamivudine and adefovir dipivoxil have never been reported.
Results: We retrospectively reviewed 1200 patients who had been tested for anti-HBV drug resistance at Beijing 
Ditan Hospital of Capital Medical University, and five patients showing multidrug resistance to lamivudine and 
adefovir dipivoxil were enrolled. Stored serum samples were used for genetic analysis, which yielded a total of 135 
clones. Entecavir+adefovir dipivoxil+lamivudine triple-resistance mutations were identified in 60 % (3/5) entecavir-
naïve patients who received sequential therapy with adefovir dipivoxil and lamivudine. Specifically, we found one 
rtM204I+rtL180 M+rtM250 V+rtA181 V clone among 23 clones from patient 1 (4.35 %), one rtM204 V+vrtL180 M 
+rtM250 V+rtA181 V clone among 24 clones from patient 2 (4.17 %), and 2 clones harboring rtM204 V+rtL180 M+
rtM250 V+rtA181 V and rtM204 V+rtL180 M+rtI169 V+rtA181 V among 20 clones from patient 3 (10.0 %). The other 
2 patients showed multidrug resistance after lamivudine/telbivudine and adefovir dipivoxil combination therapy, but 
no entecavir-resistance mutations were found in these two patients.
Conclusion: De novo entecavir+adefovir dipivoxil+lamivudine triple-resistance mutations can be induced by 
sequential therapy with adefovir dipivoxil and lamivudine in patients who never take entecavir. These results provide 
important information for sequential therapy with adefovir dipivoxil and lamivudine and the use of entecavir as a 
rescue therapy for these patients with multidrug resistance.
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Findings
Chronic hepatitis B virus (HBV) infection is estimated to 
affect approximately 120 million people in China, with 
an annual death toll of approximately 300,000, mostly 
resulting from HBV-related cirrhosis and hepatocel-
lular carcinoma (HCC) [1]. Although antiviral therapy 
with nucleoside/nucleotide analogues (NAs) and inter-
ferons (IFNs) can be used to suppress HBV replication 
and prevent disease progression, the side effects of anti-
viral drugs should be monitored regularly [2, 3]. Five 
NAs are currently approved for anti-HBV treatment in 
China, including lamivudine (LAM), adefovir dipivoxil 
(ADV), telbivudine (LdT), entecavir (ETV), and teno-
fovir disoproxil fumarate (TDF). One major concern 
for NA therapies is the emergence of HBV resistance 
after prolonged treatment, especially for drugs with 
low resistance barriers (LAM, ADV, and LdT) [2, 3]. In 
some patients, mutations causing multidrug resistance 
(MDR) may occur after sequential monotherapy with 
low-resistance barrier NAs [3]. Yim et al. reported three 
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cases of LAM+ADV-resistant patients after sequen-
tial therapy with LAM and ADV [4]. Liu et al. detected 
a ETV+ADV+LAM triple-resistant HBV strain in a 
LAM+ADV-resistant patient who had taken sequen-
tial ETV as a rescue therapy [5]. Additionally, Kim et al. 
reported six cases of ETV+ADV+LAM resistance that 
occurred after sequential therapy with LAM, ADV, and 
ETV [6].
ETV resistance mutations are commonly induced 
by ETV treatment. However, Yang et  al. reported that 
LAM-resistant HBV also had reduced susceptibil-
ity to ETV (37- to 471-fold reduction) [7]. Addition-
ally, Inoue et  al. described a patient who received 
LAM+ADV and then developed de novo ETV resist-
ance with rtM204  V+rtL180  M+rtT184 S mutations 
[8]. However, it is still not clear whether or not sequen-
tial or combination therapy with LAM and ADV induces 
ETV+ADV+LAM triple-resistance mutations. Further-
more, ETV+ADV is still used for rescue therapy in many 
LAM+ADV-resistant patients [9–11], especially in China 
where TDF is costly and not covered by the reimburse-
ment system. Therefore, we retrospectively analyzed 
chronic hepatitis B (CHB) patients in Beijing Ditan Hos-
pital of Capital Medical University in whom sequential or 
combination therapy with LAM+ADV was not success-
ful. Genetic analyses of stored serum samples revealed 
ETV+ADV+LAM triple-resistance mutations in three 
ETV-naïve patients who received sequential therapy with 
ADV+LAM.
The initial study population consisted of 1200 CHB 
patients who underwent drug resistance testing by nested 
polymerase chain reaction (PCR)-based direct sequenc-
ing at the Beijing Ditan Hospital. Written consent was 
obtained from each patient. Demographic and clinical 
data were collected using a questionnaire. Serum sam-
ples were stored at −20 °C until further analysis. Patients 
exhibiting MDR to both LAM and ADV were selected 
for the study. Clinical data were confirmed by checking 
medical records in the hospital information system. This 
study was approved by ethics committee of Beijing Ditan 
Hospital.
HBV DNA extraction was conducted using an Axy-
Prep Body Fluid Viral DNA/RNA Miniprep Kit (Corning 
Inc., Corning, NY). Nested PCR-direct sequencing was 
performed as previously described [12]. The PCR prod-
ucts were purified using a QIAquick PCR purification Kit 
(Qiagen, Valencia, CA, USA) according to the manufac-
turer’s instructions. Purified DNA was sequenced using 
an automated ABI 3730 DNA sequencer (Applied Bio-
systems, Foster City, CA, USA) at Beijing Augct Bioen-
gineering Co., Ltd. DNA sequences were aligned using 
SeqMan and EditSeq software (DNASTAR Inc., Madi-
son, WI). The HBV polymerase sequencing results were 
also used for HBV genotyping with the genotyping tool 
of the website of the National Center for Biotechnol-
ogy Information [13]. PCR-amplified HBV DNA was 
cloned into the pGEM-T easy vector (Promega, Madi-
son, WI) according to the manufacturer’s instructions. 
Clones (n = 20–38) were selected from each patient, and 
the sequences were analyzed using MegAlign software 
(DNASTAR Inc.).
Five HBV patients with MDR to both LAM/LdT 
and ADV were enrolled. The demographic and clini-
cal characteristics of the patients, together with the 
direct sequencing results of the nested PCR products, 
are shown in Table 1. HBV genotyping showed that all 5 
patients were infected with genotype C HBV.
In total, 135 clones were obtained from the five 
patients. All clones were submitted to NCBI GenBank, 
and the accession numbers are shown in Additional file 1: 
Table S1. The results of the clonal analysis are shown 
in Fig.  1. Patient 1 received ADV and LAM sequen-
tial therapy, and direct sequencing of the nested PCR 
product showed rtM204 V+rtL180 M+rtA181 V muta-
tions upon secondary virological breakthrough, whereas 
rtM204  V+rtL180  M+rtA181  V strains accounted 
for 78.26  % (18/23) of the clones in the clonal analysis. 
In addition, 17.39  % (4/23) and 13.04  % (3/23) of the 
clones harbored the rtM204 I and rtA181 T mutations, 
respectively, which were not found by direct sequenc-
ing. Moreover, one clone (4.35  %) harbored rtM204 
I+rtL180  M+rtM250  V+rtA181  V mutations, which 
resulted in resistance to LAM+ADV+ETV (Additional 
file 2: Figure S1); however, this patient had never received 
ETV therapy.
Patient 2 received ADV and LAM sequential therapy, 
and sequencing revealed rtM204 V+rtL180 M+rtA181 V 
mutations upon secondary virological breakthrough, 
whereas rtM204  V+rtL180  M+rtA181  V strains com-
prised 95.83 % (23/24) of the clones in the clonal analysis. 
Additionally, one clone (4.17 %) bore rtM204 V+rtL180 
M+rtM250  V+rtA181  V mutations, which resulted in 
resistance to LAM+ADV+ETV (Additional file 3: Figure 
S2). This patient also never received ETV therapy.
Patient 3 received ADV and LAM sequential therapy, 
and sequencing showed rtM204 V+rtL180 M+rtA181 V 
mutations upon secondary virological breakthrough, 
whereas 85.0  % (17/20) of the clones harbored 
rtM204 V+rtL180 M+rtA181 V mutations. In addition, 
one clone (5.0  %) bore rtM204  V+rtA181 T mutations. 
Moreover, two clones (10.0  %) bore ETV+LAM+ADV 
triple-resistance mutations (Additional file  4: Figure S3 
and Additional file 5: Figure S4), even though this patient 
had also never received ETV therapy.
Patient 4 received ADV+LAM for rescue therapy 
upon ADV resistance, and sequencing showed rtM204 
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I+rtA181 V+rtA181 T mutations upon secondary viro-
logical breakthrough. A high diversity of mutated strains 
was observed in the clonal analysis, with seven mutation 
patterns present in 30 clones. The rtN236 T mutation was 
not found by direct sequencing of PCR products, and no 
ETV-resistance mutations were detected in this patient.
Patient 5 received ADV+LAM for rescue therapy upon 
LAM resistance, but was later switched to LdT mono-
therapy, which was requested by the patient because of 
concerns regarding creatinine elevation. Sequencing 
identified rtM204  V+rtL180  M+rtA181  V mutations 
upon secondary virological breakthrough. All clones har-
bored rtM204  V+rtL180  M+rtA181  V mutations, con-
sistent with the sequencing results, and no de novo ETV 
resistance mutations were detected.
The possible overlapping S-gene mutations of all clones 
harboring the rtA181 T mutation were analyzed (Addi-
tional file 6: Table S2). In patient 1, 3 clones harboring the 
rtA181 T mutation had sW172*(stop codon) mutations 
in the overlapping S gene. Additionally, 1 clone and 15 
clones harboring rtA181 T mutations in in patients 3 and 
4, respectively, showed sW172* mutations.
In this study, we performed a genetic analysis with 
serum samples obtained from five patients with chronic 
HBV infection that exhibited MDR to LAM/LdT and 
ADV following sequential/combination therapy with 
LAM/LdT and ADV. Surprisingly, de novo ETV resist-
ance mutations were present in all three patients who 
received sequential therapy with ADV+LAM. Inoue 
et al. previously performed a clonal analysis and reported 
that strains with ETV resistance harbored only ETV 
resistance mutations and no ADV resistance mutations. 
However, in the present study, all three patients had HBV 
strains with MDR for ETV+LAM+ADV, although these 
MDR clones comprised only a minor population of the 
quasispecies.
There are several reports of the use of ETV as a rescue 
therapy for patients with MDR to LAM+ADV. How-
ever, Heo et al. reported that ETV monotherapy is infe-
rior as a rescue therapy in patients with MDR to LAM 
and ADV [14]. Additionally, Xu et al. reported the use of 
ETV+ADV for rescue therapy in 45 patients who failed 
to respond to treatment with multiple NAs, with 2/45 
patients showing LAM+ADV resistance at baseline. 
However, after 24 months of treatment with ETV+ADV 
treatment, one patient still did not achieve a complete 
virological response (HBV DNA  ≤500 copies/mL) (11). 
Moreover, Lim et  al. reported that ETV  +  ADV could 
be used as a rescue therapy in patients with a suboptimal 
response to LAM+ADV; however, only 28.9  % (13/45) 
of the patients achieved virological responses (HBV 
DNA < 60 IU/mL) after 52 months of therapy [15]. Nota-
bly, this study also included two patients with de novo 
ETV resistance mutations at rtT184 A and rtM250 L 
after LAM+ADV treatment, but no further clonal analy-
ses were conducted in these patients. According to these 
studies, de novo ETV-resistance mutations after sequen-
tial and/or combination therapy with LAM+ADV may 
play a role in the inferior efficacy of ETV rescue therapy 
in these patients.
The present study also indicates a need for more sensi-
tive HBV drug resistance tests in clinical practice. Direct 
sequencing of PCR products is frequently used in clini-
cal practice and trials to detect NA resistance [16, 17]; 
Table 1 Demographic and clinical characteristics of patients
ADV adefovir dipivoxil, LAM lamivudine, LdT telbivudine, PCR polymerase chain reaction, CHB chronic hepatitis B, HCC hepatocellular carcinoma, LAM + ADV LAM and 
ADV combination therapy
a ↓ indicates followed by
Patient 1 2 3 4 5
Age (years) 61 36 55 38 40
Sex F M M M M
Race Asian Asian Asian Asian Asian
Diagnosis CHB CHB HBV-related  
cirrhosis, HCC
CHB CHB
HBV genotype C C C C C
HBeAg/Anti-HBe −/+ +/− +/− +/− +/−
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Fig. 1 Genetic analysis of multidrug-resistant strains (135 clones) from patients receiving nucleoside/nucleotide analogue treatment. The expanded 
sections show de novo entecavir resistance mutations
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however, it can only identify mutations when they reach 
approximately 20  % of the total HBV quasispecies pool 
[18]. As shown in this study, direct sequencing of PCR 
products was unable to detect de novo ETV-resistant 
strains in patients 1, 2, and 3, as these strains comprised 
4.35, 4.17, and 15.0  % of the total quasispecies, respec-
tively. However, minor mutant strains can evolve to 
major strains under ETV selection pressure, and thus 
their early detection is important. More sensitive resist-
ance tests have been reported to detect mutant strains 
comprising <5 % of the total HBV quasispecies, but they 
are either costly or inconvenient for widespread use in 
China [19, 20].
The study also calls attention to the use of less potent 
NAs in combination as a rescue therapy for NA resist-
ance [2, 3]. Addition of LAM is a therapeutic option for 
ADV-resistant patients. In this study, patient 4 developed 
MDR to LAM+ADV while receiving LAM+ADV combi-
nation therapy to rescue ADV resistance. Other reports 
have described similar phenomena [8, 15]. Thus, thor-
ough and rapid inhibition of HBV replication is critical 
for combination therapy; otherwise, combination therapy 
with LAM+ADV may increase the selection pressure of 
both drugs in patients with persistent viremia.
In this study, all MDR patients were infected with gen-
otype C. we consider this is partly because genotype C is 
predominant in the northern part of China [1]. Several 
reports have indicated higher numbers of ADV or LAM 
resistance mutations in HBV genotype C compared with 
genotype B [21, 22]. However, the sample size was too 
small to establish a correlation between genotype C and 
MDR mutations.
It has been reported that the rtA181 T mutation in 
HBV may cause sW172* in the overlapping S gene in 
genotype D HBV infection [23]. In this study, all geno-
type C HBV clones harboring the rtA181 T mutation 
had sW172* mutations in the overlapping S-gene. Strains 
harboring the rtA181 T/sW172* mutation accounted 
for 13.04  % (3/23), 4.17  % (1/24), and 50.0  % (15/30) of 
the total clones in patients 1, 3, and 4, respectively. This 
also confirms that the HBV rtA181 T/sW172*mutation is 
usually detected in a mixed population with lower repli-
cation efficiency [24].
In conclusion, our results indicate that de novo 
LAM+ADV+ETV resistance mutations may be induced 
by sequential therapy with ADV+LAM in patients who 
never took ETV. These results provide important infor-
mation for administration of sequential therapy with 
ADV and LAM and for the use of ETV for rescue therapy 
in patients with MDR to ADV+LAM.
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